Ewing's sarcoma family of tumors: an overview from diagnosis to survivorship.

@article{Lahl2008EwingsSF,
  title={Ewing's sarcoma family of tumors: an overview from diagnosis to survivorship.},
  author={Meredith Lahl and Vicki L. Fisher and Kelly Laschinger},
  journal={Clinical journal of oncology nursing},
  year={2008},
  volume={12 1},
  pages={
          89-97
        }
}
The Ewing's sarcoma family of tumors (ESFT) is a malignant primary bone tumor often involving soft tissue that affects not only children but also young adults. Since 1992, with the addition of ifosfamide and etoposide to standard chemotherapy for primary tumors, much improvement has been made in the treatment of ESFT, with a primary focus on children. Though often recognized as a childhood cancer, it can affect individuals into the middle years of their lives, but little is known about the… Expand
Ewing’s Sarcoma of the Sacrum
TLDR
The use of multidrug chemotherapy, together with radiation therapy (RT) and surgery for local control, has significantly improved the prognosis of ES, even if it is still considered worse in the spine compared to other site. Expand
Metastasis of Ewing Sarcoma to the Pancreas: Case Report and Literature Review
TLDR
A rare case of ES metastasis to the pancreas is presented, and the positive outcome in this patient's case may explain the importance of prompt diagnosis in order to initiate appropriate treatment. Expand
DIAGNOSIS AND TREATMENT OF EWING ' S SARCOMA : REVIEW ARTICLE
Ewing sarcoma (ES) is an aggressive sarcoma of bone and soft tissue occurring at any age with a peak incidence in adolescents and young adults. The treatment of ES relies on a multidisciplinaryExpand
Management of Ewing Sarcoma Family of Tumors: A Short Description of a Rare Primitive Uterine pPNET and Literature Review
TLDR
The outcome of a patient with a rare primitive uterine pPNET is described and a literature review of the subject is performed, highlighting the main biological, pathological and clinical features, with a hypothesis about the possible future therapeutic approaches for these rare malignancies. Expand
Successful embryo cryopreservation immediately following a full-term delivery in a woman with newly diagnosed Ewing’s sarcoma
TLDR
A case of ovarian stimulation started a few days after a 37-week delivery in a woman newly diagnosed with Ewing’s sarcoma, which resulted in the vitrification of six good-quality embryos is reported. Expand
Ewing Sarcoma Family of Tumors
TLDR
The diagnosis and management of Ewing sarcoma is laborious and requires the correlation of multiple imaging modalities, andMultimodality medical imaging plays a great role in visualizing the tumor, documenting metastatic spread, tumor staging, associated complications, and response to therapy. Expand
Two Cases of Ewing’s Sarcoma Arising in the Ethmoid Sinus
TLDR
Two cases of Ewing’s sarcoma in the ethmoid sinus are presented, one of which is a 15-year old female patient with ethmoids sinus tumor metastated from right chest wall who received at least 10 trials of chemotherapy for Ewing's Sarcoma and the other is a 75-year-old female with non-specific medical past history except one endoscopic sinus surgery of nasal cavity. Expand
Ewing´s sarcoma
TLDR
A 71 year old Hispanic woman came to the office complaining of a 3 to 4 month history of slowly increasing right nasal congestion and was taken to the operating room, where a mass was found to be attached to the nasal septum and was easily removed with clear margins. Expand
High Efficacy of Preoperative Low-Dose Radiotherapy with Sanazole (AK-2123) for Extraskeletal Ewing's Sarcoma: A Case Report
TLDR
The combined modality of pre-operative low-dose radiotherapy with hypoxic cell radiosensitizer and adequate surgical resection might provide for the useful clinical application of extraskeletal Ewing's sarcoma treatment. Expand
High Long-term Local Control with Sacrectomy for Primary High-grade Bone Sarcoma in Children
TLDR
Despite the high incidence of neurologic deficits and complications, sacrectomy achieved local control in patients with high-grade bone sarcomas, suggesting long-term survival and adequate quality of life are possible in the pediatric population. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 25 REFERENCES
Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: predictors of survival?
TLDR
Initial presentation of disease represents the only predictor of survival identified in this small group of adult patients with Ewing sarcoma/PNET. Expand
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
TLDR
The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcomeFor patients with nonmetastatic Ewing's Sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone. Expand
The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors.
  • H. Grier
  • Medicine
  • Pediatric clinics of North America
  • 1997
TLDR
The addition of ifosfamide and etoposide to standard therapy in Ewing's sarcoma has improved survival for patients without metastases at presentation, however, outcome for patients with metastases or who develop metastases while on therapy or shortly thereafter remains poor. Expand
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
  • J. Miser, M. Krailo, +12 authors H. E. Grier
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Adding ifosfamide and etoposide to standard therapy does not improve outcomes of patients with Ewing's sarcoma or PNET of bone with metastases at diagnosis. Expand
The Role of Surgery and Resection Margins in the Treatment of Ewing’s Sarcoma
TLDR
In addition to the influence of neoadjuvant chemotherapy for higher survival rates (5-year overall survival with a good response was 80.2% versus 41.7% with a poor response), adequate surgical margins significantly affect the outcome for patients with Ewing’s sarcoma. Expand
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
  • B. Kushner, P. Meyers
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
The MSKCC experience and findings suggest that dose-intensive use of the chemotherapy agents with established activity against ES/PNET is reaching its efficacy and toxicity limits, and a major impact on prognosis awaits the development of entirely novel therapies. Expand
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
  • N. Marina, A. Pappo, +6 authors W. Meyer
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Although intensifying therapy seems feasible for 25% of patients on this study, toxicity was considerable and the noninvestigational use of dose-intensification in patients with EFT should await assessment of its impact on disease-free survival. Expand
Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study.
  • M. Nesbit, E. Gehan, +7 authors J. Kissane
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1990
TLDR
A total of 342 previously untreated eligible children were entered into the first Intergroup Ewing's Sarcoma Study (IESS) between May 1973 and November 1978 and patient characteristics related to prognosis and overall survival experience were primary site (nonpelvic patients were most favorable) and patient age (younger patients were more favorable). Expand
Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.
TLDR
71 children with sarcomas were treated in a prospective pilot study to determine whether granulocyte colony stimulating factor (G-CSF) permits compression of the interval between chemotherapy cycles, and event-free survival is comparable with or superior to that in recent large studies. Expand
Supportive care of children with cancer : current therapy and guidelines from the Children's Oncology Group
TLDR
The third edition features a new chapter on recognition, prevention, and remediation of burnout in pediatric oncology staff members, while throughout the book, chapters have been revised and updated to reflect the impact of new antibiotic agents, new antiemetics, and new approaches to pain management. Expand
...
1
2
3
...